Teva Pharmaceutical Industries LTD DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NYSE
Teva Pharmaceutical Industries Limited reports strong 2025 performance, advancing its 'Pivot to Growth' strategy with significant gains in innovative medicines and debt reduction, while outlining ambitious 2026 goals.
NYSE
Teva Pharmaceutical Industries Limited will hold its annual shareholder meeting virtually on June 5, 2025, to vote on director elections, executive compensation, and other key proposals.
NYSE
Teva Pharmaceutical Industries is asking shareholders to vote on key proposals at its upcoming annual meeting, including the election of directors, executive compensation, and amendments to director compensation policies.
NYSE
Teva Pharmaceutical Industries Limited will hold its annual shareholder meeting virtually on June 6, 2024, to vote on director appointments, executive compensation, and auditor selection.
NYSE
Teva Pharmaceutical's proxy statement highlights the company's 'Pivot to Growth' strategy, board refreshment, and key proposals for the 2024 annual meeting.